Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
Website:
http://www.atyrpharma.comNext earnings report:
09 August 2024Last dividends:
N/ANext dividends:
N/APrice
regular market | Thu, 27 Jun 2024 13:30:00 GMTDividend
Analysts recommendations
Institutional Ownership
Included in screeners
What type of business is aTyr Pharma?
aTyr Pharma, Inc., a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. Its lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase III clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD. The company is developing ATYR0101, a fusion protein derived from a domain of aspartyl-tRNA synthetase that is in preclinical development for the treatment of fibrosis; and ATYR0750, a domain of alanyl-tRNA synthetase for the treatment of liver disorders. It has collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of efzofitimod for ILDs in Japan. aTyr Pharma, Inc. was incorporated in 2005 and is headquartered in San Diego, California.
What sector is aTyr Pharma in?
aTyr Pharma is in the Healthcare sector
What industry is aTyr Pharma in?
aTyr Pharma is in the Biotechnology industry
What country is aTyr Pharma from?
aTyr Pharma is headquartered in United States
What is aTyr Pharma website?
https://www.atyrpharma.com
Is aTyr Pharma in the S&P 500?
No, aTyr Pharma is not included in the S&P 500 index
Is aTyr Pharma in the NASDAQ 100?
No, aTyr Pharma is not included in the NASDAQ 100 index
Is aTyr Pharma in the Dow Jones?
No, aTyr Pharma is not included in the Dow Jones index
When does aTyr Pharma report earnings?
The next expected earnings date for aTyr Pharma is 09 August 2024